Here’s a practical side-by-side to help you compare metoprolol and bisoprolol.
What they have in common
- Both are beta-1 selective (cardioselective) beta-blockers used for high blood pressure, angina, certain heart rhythm problems, and heart failure with reduced ejection fraction (HFrEF).
- They slow the heart rate and lower blood pressure; both can cause similar side effects: bradycardia, fatigue, dizziness, low blood pressure; may mask hypoglycemia; should not be stopped abruptly.
- Both can interact with other heart meds (especially non-dihydropyridine calcium channel blockers like diltiazem/verapamil) and with insulin or other diabetes meds.
Key differences
- Selectivity and CNS effects
- Metoprolol: more lipophilic, crosses the brain more easily. This can mean more fatigue or sleep/dream effects in some people.
- Bisoprolol: more hydrophilic, tends to cause fewer CNS side effects in many patients.
- Dosing forms and convenience
- Metoprolol comes as tartrate (often twice daily) and succinate (extended-release, usually once daily).
- Bisoprolol is typically given once daily.
- Pharmacokinetics and metabolism
- Metoprolol is largely metabolized by the liver (CYP2D6) and has potential interactions with drugs that affect that enzyme.
- Bisoprolol is less dependent on CYP metabolism and is eliminated by both liver and kidneys, but dosing should be adjusted in kidney disease.
- What they’re especially used for
- Hypertension and angina: both are common choices.
- Heart failure (HFrEF): both have solid evidence; metoprolol succinate (extended-release) and bisoprolol have proven mortality benefits. Carvedilol is another strong option in HF.
- Post-heart attack (MI): metoprolol has a long-standing role with robust trial data; bisoprolol also has HF/MI-related evidence in some trials.
- Atrial fibrillation/rapid heart rate: both can be used for rate control.
Practical dosing notes
- Metoprolol tartrate: often twice daily.
- Metoprolol succinate (extended-release): once daily.
- Bisoprolol: usually once daily.
- Start low and titrate slowly while monitoring heart rate, blood pressure, and symptoms.
- If you have COPD or asthma, both are cardioselective but still should be used with caution; many patients tolerate either well, but some clinicians prefer one over the other based on patient history.
Safety considerations
- Do not stop abruptly; taper if discontinuing.
- Watch for excessive bradycardia, dizziness, or very low blood pressure.
- Caution with other heart meds (e.g., certain calcium channel blockers, other antiarrhythmics) to avoid too slow heart rate or AV block.
- In diabetes, monitor for masking of hypoglycemia symptoms.
Choosing between them (quick guide)
- If you want once-daily dosing and potentially fewer CNS effects: bisoprolol is often preferred.
- If you need a preparation that can be dosed twice daily or you’re choosing specifically for certain HF or post-MI evidence from older trials, metoprolol (tartrate or succinate) is a solid option.
- For heart failure, either metoprolol succinate or bisoprolol is reasonable (per guidelines), with the exact choice often guided by tolerability, comorbidities, and clinician experience.
- For COPD/asthma: cardioselective beta-blockers like metoprolol or bisoprolol can be used with caution; inhaled symptoms and tolerance vary.
If you share your specific context (primary condition, other meds, COPD/asthma status, kidney/liver function, pregnancy status, and whether you prefer once-daily dosing), I can tailor the guidance more precisely and point out expected dosing ranges and monitoring.